SPRY Stock: Price, Forecast, Financials & AI Analysis

Loading...

01/14 15:24

SPRY Stock: Price, Forecast, Financials & AI Analysis

High

11.735

Open

11.300

VWAP

11.39

Vol

803.14K

Mkt Cap

1.12B

Low

11.140

Amount

9.15M

EV/EBITDA(TTM)

--

Total Shares

98.85M

EV

926.00M

EV/OCF(TTM)

--

P/S(TTM)

8.21

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

Show More

Events Timeline

(ET)

2026-01-09

09:40:00

Raymond James: Strong Buy on ARS Pharmaceuticals, Anaphylm Market Entry May Be Delayed by a Year

2025-12-29 (ET)

2025-12-29

08:10:00

ARS Pharmaceuticals Receives China Approval for Neffy to Treat Allergic Reactions

2025-11-10 (ET)

2025-11-10

06:05:50

ARS Pharmaceuticals announces Q3 earnings per share of 52 cents, surpassing consensus estimate of 49 cents.

2025-11-04 (ET)

2025-11-04

08:25:00

ARS Pharmaceuticals Introduces 'Get Neffy on Us' Initiative

2025-10-08 (ET)

2025-10-08

08:02:25

ARS Pharmaceuticals Secures Positive Ruling from EPO Regarding Neffy

News

an image of Benzinga

ARS Pharmaceuticals Stock Rises 18.86% Following FDA Update on Rival Aquestive

an image of Benzinga

Aquestive Therapeutics Faces 40% Stock Drop After FDA Identifies Deficiencies in Anaphylm NDA

an image of NASDAQ.COM

01-02NASDAQ.COM

ARS Pharma's Neffy Approved in China for Allergy Treatment

an image of Globenewswire

2025-12-29Globenewswire

ARS Pharma's neffy Approved as First Community Use Epinephrine Product in China

an image of Newsfilter

2025-12-29Newsfilter

ARS Pharma's Neffy Approved in China for Allergy Treatment

an image of Globenewswire

2025-11-26Globenewswire

ARS Pharmaceuticals to Showcase neffy® at Piper Sandler Healthcare Conference

5 Analyst Rating

Wall Street analysts forecast SPRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRY is 30.00 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

25.00

Averages

30.00

High

35.00

Current: 0.000

Low

25.00

Averages

30.00

High

35.00

Oppenheimer

Oppenheimer

Outperform

maintain

$40 -> $35

Al Analysis

2025-11-11

Reason

Oppenheimer

Oppenheimer

Price Target

$40 -> $35

Al Analysis

2025-11-11

maintain

Outperform

Reason

Oppenheimer lowered the firm's price target on ARS Pharmaceuticals to $35 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported strong Q3 financials with $32.5M in revenue, beating consensus and surpassing OpCo estimates of $28.7M/$29.4M, respectively. Neffy's momentum reflects the DTC lift, back-to-school demand, and broader prescriber adoption across new epinephrine segments, with upcoming tailwinds from the virtual campaign, growing real-world evidence, and formulary adds in 2026, Oppenheimer adds.

Roth Capital

Kyle Bauser

initiated

$30

2025-11-04

Reason

Roth Capital

Kyle Bauser

Price Target

$30

2025-11-04

initiated

Reason

Roth Capital analyst Kyle Bauser resumed coverage of ARS Pharmaceuticals with a Buy rating and $30 price target. The firm is anticipating significant revenue growth from the rapid adoption of the company's signature product, neffy, which is an innovative intranasal epinephrine device for Type 1 allergic reactions, including anaphylaxis, the analyst tells investors in a research note. The ability of neffy to take significant share from outdated epinephrine auto-injectors is currently underappreciated, particularly given the recent sales growth to date, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SPRY

Unlock Now

Valuation Metrics

The current forward P/E ratio for ARS Pharmaceuticals Inc (SPRY.O) is -7.61, compared to its 5-year average forward P/E of -11.43. For a more detailed relative valuation and DCF analysis to assess ARS Pharmaceuticals Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-11.43

Current PE

-7.61

Overvalued PE

-6.97

Undervalued PE

-15.89

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-1.30

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.20

Undervalued EV/EBITDA

-4.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

5759.43

Current PS

6.92

Overvalued PS

25289.45

Undervalued PS

-13770.59

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is ARS Pharmaceuticals Inc (SPRY) stock price today?

The current price of SPRY is 11.705 USD — it has increased 3.49 % in the last trading day.

What is ARS Pharmaceuticals Inc (SPRY)'s business?

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

What is the price predicton of SPRY Stock?

Wall Street analysts forecast SPRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRY is30.00 USD with a low forecast of 25.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is ARS Pharmaceuticals Inc (SPRY)'s revenue for the last quarter?

ARS Pharmaceuticals Inc revenue for the last quarter amounts to 32.50M USD, increased 1471.62 % YoY.

What is ARS Pharmaceuticals Inc (SPRY)'s earnings per share (EPS) for the last quarter?

ARS Pharmaceuticals Inc. EPS for the last quarter amounts to -0.52 USD, increased 160.00 % YoY.

How many employees does ARS Pharmaceuticals Inc (SPRY). have?

ARS Pharmaceuticals Inc (SPRY) has 155 emplpoyees as of January 14 2026.

What is ARS Pharmaceuticals Inc (SPRY) market cap?

Today SPRY has the market capitalization of 1.12B USD.